Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$2.42 USD
+0.15 (6.61%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.41 -0.01 (-0.41%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
RGLS 2.42 +0.15(6.61%)
Will RGLS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RGLS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RGLS
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
RGLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regulus (RGLS) Surges on Enrollment Completion for RGLS8429
Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study
Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug
Other News for RGLS
Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD
Regulus files to sell 62.5M shares of common stock for holders
Regulus files to sell 62.5M shares of common stock for holders
Buy Rating on Regulus’s RGLS8429 Backed by Positive Phase 1b Data and Unmet ADPKD Treatment Needs
Analysts Offer Insights on Healthcare Companies: Regulus (RGLS), Axsome Therapeutics (AXSM) and Olink Holding (OLK)